4.1 Article

Diabetic neuropathy: An intensive review

Journal

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
Volume 61, Issue 2, Pages 160-173

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/ajhp/61.2.160

Keywords

amitriptyline; analgesics and antipyretics; anticonvulsants; antidepressants; antiinflammatory agents; antioxiclants; antiparkinson agents; antitussives; bupropion; caffeine; capsaicin; cardiac drugs; central nervous system stimulants; citalopram; classification; clonidine; desipramine; dextromethorphan; diabetic neuropathies; dihydroergotamine; enzyme inhibitors; epidemiology; erythromycin; fludrocortisone; fluoxetine; gabapentin; gastrointestinal drugs; hypotensive agents; lamotrigine; levodopa; macrolides; metoclopramide; mexiletine; midodrine; octreotide; opiates; oxcarbazepine; paroxetine; phenytoin; ruboxistaurin; steroids; cortico-; sympatholytic agents; sympathomimetic agents; thioctic acid; tramadol; transcutaneous electric nerve stimulation; venlafaxine; zonisamide

Ask authors/readers for more resources

Purpose. The epidemiology, classification, pathology, and treatment of diabetic neuropathy are reviewed. Summary. Diabetic peripheral neuropathy is a common complication of diabetes that can cause significant morbidity and mortality. Some 30% of hospitalized and 20% of community-dwelling diabetes patients have peripheral neuropathy; the annual incidence rate is approximately 2%. The primary risk factor is hyperglycemia. Sensorimotor neuropathy is marked by pain, paresthesia, and sensory loss. Cardiac autonomic neuropathy (CAN) may contribute to myocardial-infarction, malignant arrhythmia, and-sudden death. Gastroparesis is the most debilitating complication of gastrointestinal autonomic neuropathy. Genitourinary autonomic neuropathy can cause sexual dysfunction and neurogenic bladder. The pathology of diabetic neuropathy involves oxidative stress, advanced glycation end products; polyol pathway flux, and protein kinase C activation; all contribute to microvascular disease and nerve dysfunction. For symptom management current evidence from clinical trials supports the use of desipramine, amitriptyline, capsaicin, tramadol, gabapentin, bupropion, and venlafaxine as preferred medications. Citalopram, nonsteroidal antiinflammatory drugs, and opioid analgesics may be used as adjuvant agents. Lamotrigine, oxcarbazepine, paroxetine, levodopa, and alpha-lipoic acid are alternatives considerations. Evidence supporting the use of zonisamide, fluoxetine, mexiletine, dextromethorphan, and phenytoin is considered equivocal. Complementary therapies have also shown efficacy. The symptoms of CAN may be ameliorated with fludrocortisone, clonidine, midodrine, dihydroergotamine or caffeine, octreotide, and beta-blockers. Gastroparesis may be treated with metoclopramide or erythromycin. The most promising disease-modifying therapy is ruboxistaurin, which is in Phase III trials. Glycemic control remains the foundation of prevention and the prerequisite of adequate treatment. Conclusion. Diabetic neuropathy is a many-faceted complication of diabetes that can be managed symptomatically with an array of drugs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available